Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ACTRIMS 2021 | Assessing novel biomarkers: retinal layer atrophy in PMS vs. RRMS

Elias Sotirchos, MD, Johns Hopkins University School of Medicine, Baltimore, MD, shares the findings of a study of retinal later atrophy in multiple sclerosis (MS) using serial optical coherence tomography (OCT). OCT-derived retinal measures have been suggested as a potential biomarker of neurodegeneration in progressive MS. Thus, patients with progressive MS, relapsing-remitting MS (RRMS) and control participants were assessed using OCT for a median of 3.7 years. Results showed that progressive MS was associated with faster retinal atrophy compared to RRMS, independent of age. Inner nuclear layer (INL) and outer nuclear layer (ONL) thinned faster in PMS than in RRMS and controls, and thinning rate was not impacted by disease modifying therapies, highlighting these measures as potential novel biomarkers of neurodegeneration in MS. This interview took place during the ACTRIMS Forum 2021.


Dr. Sotirchos has served on scientific advisory boards for Alexion, Viela Bio and Genentech, and has received speaker honoraria from Viela Bio and Biogen.